Related references
Note: Only part of the references are listed.Treatment of Parkinson's disease with trophic factors
Amie L. Peterson et al.
NEUROTHERAPEUTICS (2008)
Randomized study of the OF Bioavailability of different formulations of coenzyme Q10 (Ubiquinone)
Radu Constantinescu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
Ira Shoulson et al.
NEUROLOGY (2007)
Assessment of the progression of Parkinson's disease: a metabolic network approach
Thomas Eckert et al.
LANCET NEUROLOGY (2007)
Changes in network activity with the progression of Parkinson's disease
Chaorui Huang et al.
BRAIN (2007)
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys
Christopher D. Herzog et al.
MOVEMENT DISORDERS (2007)
Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease
Y.-Q. Xue et al.
NEUROSCIENCE (2007)
Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation
Phylinda L. S. Chan et al.
PHARMACEUTICAL RESEARCH (2007)
Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease
Mehdi Gasmi et al.
MOLECULAR THERAPY (2007)
Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): Process, format, and clinimetric testing plan
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2007)
Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system
Randy L. Hunter et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Restoration of the striatal dopamine synthesis for Parkinson's disease: Viral vector-mediated enzyme replacement strategy
Thomas Carlsson et al.
CURRENT GENE THERAPY (2007)
TCH346 as a neuroprotective drug in Parkinsons disease: a double-blind, randomised, controlled trial
C. Warren Olanow et al.
LANCET NEUROLOGY (2006)
Neuroprotection in Parkinson models varies with toxin administration protocol
David W. Anderson et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2006)
Creatine supplementation in Parkinson disease:: A placebo-controlled randomized pilot trial
A. Bender et al.
NEUROLOGY (2006)
Symptom relief in Parkinson disease by safinamide - Biochemical and clinical evidence of efficacy beyond MAO-B inhibition
F. Stocchi et al.
NEUROLOGY (2006)
Selegiline slows the progression of the symptoms of Parkinson disease
S Pålhagen et al.
NEUROLOGY (2006)
Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology
O Suchowersky et al.
NEUROLOGY (2006)
Pergolide versus levodopa monotherapy in early Parkinson's disease patients:: The PELMOPET study
WH Oertel et al.
MOVEMENT DISORDERS (2006)
The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease
O Schillaci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2005)
L-DOPA administration enhances 6-hydroxydopamine generation
H Maharaj et al.
BRAIN RESEARCH (2005)
Selective vulnerability of dopaminergic neurons to microtubule depolymerization
Y Ren et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
CG Goetz et al.
MOVEMENT DISORDERS (2005)
Parkin gene therapy for α-synucleinopathy:: A rat model of Parkinson's disease
M Yamada et al.
HUMAN GENE THERAPY (2005)
A responsive outcome for Parkinson's disease neuroprotection futility studies
JJ Elm et al.
ANNALS OF NEUROLOGY (2005)
The role of radiotracer imaging in Parkinson disease
B Ravina et al.
NEUROLOGY (2005)
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials
P Guimaraes et al.
CLINICAL TRIALS (2005)
Levodopa in the treatment of Parkinson's disease: Current controversies
CW Olanow et al.
MOVEMENT DISORDERS (2004)
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease
EJ Benner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization
RM Canet-Avilés et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease
E Diguet et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2004)
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease
DJ Brooks et al.
EXPERIMENTAL NEUROLOGY (2003)
Molecular pathways of neurodegeneration in Parkinson's disease
TM Dawson et al.
SCIENCE (2003)
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease
HL Chen et al.
ARCHIVES OF NEUROLOGY (2003)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
AL Whone et al.
ANNALS OF NEUROLOGY (2003)
Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B
W Tatton et al.
JOURNAL OF NEURAL TRANSMISSION (2003)
Neuroprotective agents for clinical trials in Parkinson's disease - A systematic assessment
BM Ravina et al.
NEUROLOGY (2003)
Oxidative stress in Parkinson's disease
P Jenner
ANNALS OF NEUROLOGY (2003)
Neuroprotective strategies in Parkinson's disease - An update on progress
S Mandel et al.
CNS DRUGS (2003)
A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa:: an 18F-dopa PET study
JS Rakshi et al.
JOURNAL OF NEURAL TRANSMISSION (2002)
Do dopamine agonists or levodopa modify Parkinson's disease progression?
K Marek et al.
EUROPEAN JOURNAL OF NEUROLOGY (2002)
Effects of coenzyme Q10 in early Parkinson disease -: Evidence of slowing of the functional decline
CW Shults et al.
ARCHIVES OF NEUROLOGY (2002)
Neuroprotection by propargylamines in Parkinson's disease - Suppression of apoptosis and induction of prosurvival genes
W Maruyama et al.
NEUROTOXICOLOGY AND TERATOLOGY (2002)
Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma
NA Abramova et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2002)
Neuroprotection by adenosine A(2A) receptor blockade in experimental models of Parkinson's disease
K Ikeda et al.
JOURNAL OF NEUROCHEMISTRY (2002)
A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease
J Jankovic et al.
PARKINSONISM & RELATED DISORDERS (2002)
The effect of deprenyl washout in patients with long-standing Parkinson's disease
R Djaldetti et al.
JOURNAL OF NEURAL TRANSMISSION (2002)
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
YS Du et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum
Y He et al.
BRAIN RESEARCH (2001)
Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol
W Maruyama et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Neuroprotective effects of pramipexole in young and aged MPTP-treated mice
DW Anderson et al.
BRAIN RESEARCH (2001)
Freezing of gait in PD - Prospective assessment in the DATATOP cohort
N Giladi et al.
NEUROLOGY (2001)
Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist
K Tanaka et al.
NEUROCHEMICAL RESEARCH (2001)
Are dopamine receptor agonists neuroprotective in Parkinson's disease?
WD Le et al.
DRUGS & AGING (2001)
The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study
B Ferger et al.
BRAIN RESEARCH (2000)
Pramipexole vs levodopa as initial treatment for Parkinson disease - A randomized controlled trial
R Holloway et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Increase of Bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole
K Takata et al.
BRAIN RESEARCH (2000)
Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice
LL Zou et al.
NEUROSCIENCE LETTERS (2000)
Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine
TQ Vu et al.
JOURNAL OF NEURAL TRANSMISSION (2000)
Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection
WD Le et al.
JOURNAL OF NEURAL TRANSMISSION (2000)
Share Paper
